German researchers tie cold viruses used to deliver Covid-19 vaccine to rare blood clot risk

German researchers tie cold viruses used to deliver Covid-19 vaccine to rare blood clot risk
German researchers tie cold viruses used to deliver Covid-19 vaccine to rare blood clot risk

Hello and welcome to the details of German researchers tie cold viruses used to deliver Covid-19 vaccine to rare blood clot risk and now with the details

Nevin Al Sukari - Sana'a - Scientists and US and European drug regulators have been searching for an explanation for what is causing the rare but potentially deadly clots accompanied by low blood platelet counts, which have led some countries to halt or limit use of the AstraZeneca and J&J vaccines. ― Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


BERLIN, May 27 ― German researchers yesterday said that based on laboratory research, they believed they have found the cause of the rare but serious blood clotting events among some people who received Covid-19 vaccines made by AstraZeneca Plc and Johnson & Johnson.

The researchers, in a study not yet reviewed by experts, said Covid-19 vaccines that employ adenovirus vectors ― cold viruses used to deliver vaccine material ― send some of their payload into the nucleus of cells, where some of the instructions for making coronavirus proteins can be misread. The resulting proteins could potentially trigger blood clot disorders in a small number of recipients, they suggest.

Scientists and US and European drug regulators have been searching for an explanation for what is causing the rare but potentially deadly clots accompanied by low blood platelet counts, which have led some countries to halt or limit use of the AstraZeneca and J&J vaccines. Other scientists have suggested competing theories for the clotting condition.

Johnson & Johnson, in an emailed statement said: “We are supporting continued research and analysis of this rare event as we work with medical experts and global health authorities. We look forward to reviewing and sharing data as it becomes available.” AstraZeneca declined to comment.

Researchers at the Goethe-University of Frankfurt and other sites explained in their paper that vaccines using a different technology known as messenger RNA (mRNA), such as those developed by BioNTech SE with partner Pfizer Inc and Moderna Inc, deliver the genetic material of the coronavirus spike protein only to fluid found inside cells, not to the nucleus of the cells. “All mRNA-based vaccines should represent safe products,” the paper said.

The paper suggests that vaccine makers using adenovirus vectors could modify the sequence of the spike protein “to avoid unintended splice reactions and to increase the safety of these pharmaceutical products.” ― Reuters

These were the details of the news German researchers tie cold viruses used to deliver Covid-19 vaccine to rare blood clot risk for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Bangkok to convert disused train carriages into Covid-19 ward
NEXT Deadly heat wave slams Canada, US